A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations
← catalyst calendarSponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
136actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-06 | actual | When the study began enrolling |
| Primary completion | 2025-08-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-19 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Intervention
- Drug: Povetacicept
Primary outcomes
what the primary-completion date above is the date OFArea Under the Concentration Versus Time Curve From the Time of Dosing to 28 Days (AUC0-28d) of Free Povetacicept
measured From Day 1 up to Day 30
Maximum Observed Plasma Concentration (Cmax) of Free Povetacicept
measured From Day 1 up to Day 30
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed